In the 1950’s scientists still were casting a broad net in their search for viable selective serotonin reuptake inhibitors. Research was taking place not only in pharmaceutical laboratories, but in audio-visual laboratories as well. In 1956, Dr. Ernest Edward Kovacs – quite by accident, while examining a rapidly pendulating reversed Chivas Regal label – discovered the psychotropic audio-visual articulation, nairobi-3, with the following molecular structure:
Dr. Kovacs and his associates produced a prototype of nairobi-3 and tested it in on 30,000 volunteers in a placebo-controlled trial. (The placebo administered was B-bop A-luba.) 87.89% of the group
receiving nairobi-3 reported a marked decrease in feelings of depression, while only 5.25% of those receiving B-bop A-luba reported a decrease in depression.
Dr. Kovacs’ work on nairobi-3 continued until his untimely death, in 1962, in an automobile accident. At the time there was widespread suspicion that Dr. Kovacs’ “accident” was an assassination by the pharmaceutical industry, which was concerned that, once perfected, nairobi-3 would obviate any need on the depressed public’s part for prescription remedies. There has never been any confirmation of those rumors.
With the death of Dr. Kovacs, research on nairobi-3 ceased until 1972, when nairobi-3 was revisited by Dr. Harry Edward Nilsson III. Taking the basic A/V articulation developed by Dr. Kovacs, Dr. Nilsson found that the addition of lime (CaO) to the Kovacs formulation eliminated the problematical side effects of nairobi-3, which included OMR (obsessive melody retention) and nightmares (experienced mostly by patients under 10 years old).
When tests of Dr. Nilsson’s new formulation, lime-ND, were conducted (using DNg A-ling as the placebo) it was found that lime-ND
Dr. Kovacs’ work on nairobi-3 continued until his untimely death, in 1962, in an automobile accident. At the time there was widespread suspicion that Dr. Kovacs’ “accident” was an assassination by the pharmaceutical industry, which was concerned that, once perfected, nairobi-3 would obviate any need on the depressed public’s part for prescription remedies. There has never been any confirmation of those rumors.
With the death of Dr. Kovacs, research on nairobi-3 ceased until 1972, when nairobi-3 was revisited by Dr. Harry Edward Nilsson III. Taking the basic A/V articulation developed by Dr. Kovacs, Dr. Nilsson found that the addition of lime (CaO) to the Kovacs formulation eliminated the problematical side effects of nairobi-3, which included OMR (obsessive melody retention) and nightmares (experienced mostly by patients under 10 years old).
When tests of Dr. Nilsson’s new formulation, lime-ND, were conducted (using DNg A-ling as the placebo) it was found that lime-ND
was almost as effective as nairobi-3 in treating depression.
By this time, of course, the pharmaceutical industry had solidified its grip on anti-depressant development and Dr. Nilsson prudently kept his research into psychotropic A/V articulation low-key and under drug companies’ radar. Nevertheless, in 1994 Dr. Nilsson too, like Dr. Kovacs, met an untimely death.
While there is no evidence whatsoever that anyone in the pharmaceutical industry engineered Dr. Nilsson’s congestive cardiac failure, it was noted by activists in the beleaguered A/V anti-depressant field that the price of Eli Lilly & Co. shares shot up after the announcement of Dr. Nilsson’s death – “inexplicably,” according to the Wall Street Journal.
Someday, the groundbreaking accomplishments of Drs. Kovacs and Nilsson in fighting depression will be hailed by the psychiatric establishment. Perhaps, thanks to technological advances and 21st century experiments in molecular harmony, someone even will find a way to improve on Dr. Nilsson’s refinement of Dr. Kovacs’ original stroke of genius. Perhaps, but it is hard to imagine.
By this time, of course, the pharmaceutical industry had solidified its grip on anti-depressant development and Dr. Nilsson prudently kept his research into psychotropic A/V articulation low-key and under drug companies’ radar. Nevertheless, in 1994 Dr. Nilsson too, like Dr. Kovacs, met an untimely death.
While there is no evidence whatsoever that anyone in the pharmaceutical industry engineered Dr. Nilsson’s congestive cardiac failure, it was noted by activists in the beleaguered A/V anti-depressant field that the price of Eli Lilly & Co. shares shot up after the announcement of Dr. Nilsson’s death – “inexplicably,” according to the Wall Street Journal.
Someday, the groundbreaking accomplishments of Drs. Kovacs and Nilsson in fighting depression will be hailed by the psychiatric establishment. Perhaps, thanks to technological advances and 21st century experiments in molecular harmony, someone even will find a way to improve on Dr. Nilsson’s refinement of Dr. Kovacs’ original stroke of genius. Perhaps, but it is hard to imagine.
RSS Feed